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Abstract: The aim of this study was to analyze the relationship between statin use along 
with serum cholesterol levels and prostate cancer (PCa) detection and aggressiveness. 
Statin users of three years or more and serum cholesterol levels (SC) were assessed in  
2408 men scheduled for prostate biopsy. SC was classified as normal (NSC: <200 mg/dL) 
or high (HSC: >200 mg/dL). High-grade PCa (HGPCa) was considered if the Gleason score 
was greater than 7. Statin users comprised 30.9% of those studied. The PCa detection rate 
was 31.2% of men on statins and 37% of non-statin users (p < 0.006). The PCa detection rate 
was 26.3% in men with NSC and 40.6% in those with HSC (p < 0.001). In the subset of NSC 
men, the PCa rate was 26.5% for statin users and 26.2% for non-users (p = 0.939), while in 
men with HSC, the PCa rate was 36.4% for statin users and 42.0% for non-statin users  
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(p = 0.063). The HGPCa rate was 41.8% for statin users and 32.5% for non-users  
(p = 0.012). NSC men had a 53.8% rate of HGPCa, while the rate was only 27.6% in HSC 
men (p < 0.001). NSC men on statins had an HGPCa rate of 70.2%, while non-statin users 
had a rate of 41.2% (p < 0.001). The HGPCa rate for HSC men on statins was 18.8%, while 
the rate was 30.0% (p = 0.011) for non-users. Logistic regression analysis suggested that 
serum cholesterol levels could serve as an independent predictor of PCa risk, OR 1.87  
(95% CI 1.56–2.24) and HGPCa risk, OR 0.31 (95% CI 0.23–0.44), while statin usage  
could not. Statin treatment may prevent PCa detection through serum cholesterol-mediated 
mechanisms. A disturbing increase in the HGPCa rate was observed in statin users who 
normalized their serum cholesterol. 
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1. Introduction 
Prostate cancer (PCa) is the most commonly diagnosed neoplasm among men in Europe and  
the US [1,2]. In addition, within the same geographic areas, hypercholesterolemia is one of the most 
frequent conditions observed in men at the age of PCa risk [3]. Statins (HMG-CoA reductase inhibitors), 
a class of cholesterol-lowering drugs, are the second most prescribed therapeutic medication after 
painkillers [4]. Therefore, examining the relationship between PCa, statins use and serum cholesterol 
would seem reasonable, especially taking into consideration recent findings in the literature. 
The relationship between serum cholesterol and the incidence of PCa and its mortality have been 
studied by several groups with inconsistent results. Some studies found a positive association between 
serum cholesterol and PCa mortality [5,6], while others revealed either an inverse relationship [7,8]  
or no overall association with the incidence of PCa [9–13]. Five recent reports suggested that men  
with low serum cholesterol are less likely to have high-grade PCa, although in those studies, serum 
cholesterol was not associated with the incidence of PCa [11–15]. On the other hand, several 
epidemiological studies investigated the association between statins use and the overall incidence of 
cancer. These studies were generally designed to investigate the effects of statins on cardiovascular 
disease, usually with cancer incidence as a secondary endpoint or adverse effect finding [16].  
Several recent studies have examined the direct relationship between statins and PCa incidence, and 
some of them have shown an inverse relationship between the use of statins and PCa risk [17–21].  
In contrast, other studies reported largely inconclusive or negative results when correlating statin use 
and PCa risk [4,22]. Finally, other studies have related the use of statins to a reduced risk of advanced 
or aggressive PCa [4,13,22–25]. The mechanisms by which statins may influence prostate carcinogenesis 
could be mediated through serum cholesterol reduction and its influence on testosterone synthesis. It is 
also possible that they have direct anti-tumor action through the inhibition of Ras superfamily 
isoprenylation and its apoptotic action [26]. 
The aim of our study was to explore whether the reduction of serum cholesterol through statin use 
influences the risk of PCa detection and tumor aggressiveness. 
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2. Results and Discussion 
2.1. Results 
In this cohort study, a subset of 744 men (30.9%) was identified as statin users for more than three 
years, and 1496 men (62.1%) were classified as having HSC. The HSC rate among statin users was 
47.3% (352/744), while it was 68.7% (1144/1664) among the non-statin users. The overall PCa 
detection rate was 35.2% (848/2408), and the rate of HGPCa detection was 28.3% (240/848). 
The median level of serum cholesterol levels (SC) was 222 mg/dL in men with PCa and 211 mg/dL 
in those without PCa, p < 0.001. The rate of chronic statin use, defined as more than three years  
of prior statins treatment, was 27.4% in men with PCa and 32.8% in men without PCa, p < 0.001.  
The age and serum prostate-specific antigen (PSA) were significantly higher in men with PCa. The 
testosterone level was significantly decreased in men with PCa, while the body mass index was found 
to be similar in both groups (Table 1). 
Table 1. Clinical characteristics according to the diagnosis of prostate cancer. 
Clinical Feature Without PCa With PCa p Value 
Age, years * 67 (46–86) 70 (52–86) 0.001 
Body mass index *, kg/m2 27.5 (18.4–45.0) 27.7 (19.0–46.0) 0.524 
Serum PSA *, ng/mL 6.9 (0.7–43.7) 7.3 (2.8–1280) 0.001 
Serum cholesterol *, mg/dL 211 (101–303) 222 (101–309) 0.001 
Statins use, n° (%) 512/1560 (32.8) 232/848(27.4) 0.006 
*, values expressed in median (range). 
The median level of SC was 204 mg/dL in men with PCa and 225 in those without PCa, p < 0.001. 
The rate of statin use was 33.3% in men with PCa and 25% in men without PCa, p < 0.017. The age, 
serum PSA and body mass index were significantly higher in men with PCa, while the testosterone 
level was similar in both groups (Table 2). 
Table 2. Clinical characteristics according to the diagnosis of high-grade prostate cancer. 
Clinical Feature Without HGPCa With HGPCa p Value 
Age, years * 68 (52–83) 74 (53–86) 0.001 
Body mass index *, kg/m2 27.2 (20.7–46.0) 27.8 (19.0–34.8) 0.008 
Serum PSA *, ng/mL 6.3 (2.8–69.6) 10.7 (3.0–1280) 0.001 
Serum cholesterol *, mg/dL 225 (101–309) 204 (142–303) 0.001 
Statins use, n° (%) 152/608 (25.0) 80/240 (33.3) 0.017 
*, values expressed in median (range). 
A binary logistic regression analysis was conducted, in order to determine whether SC levels and 
statin use were independent predictors of PCa and HGPCa. Age, serum PSA, serum testosterone and body 
mass index were also included as co-variables. We observed that SC was an independent predictor of PCa 
and HGPCa detection, while statin use was not. When SC was considered as normal vs. high, we found  
that HSC increased the risk of PC detection, OR 1.870 (95% CI 1.557–2.245), p = 0.001. Contrarily, HSC 
decreased the risk of HGPCa detection, OR 0.314 (95% CI 0.226–0.436), p = 0.002 (Table 3). 
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Table 3. Binary logistic regression of predictors of prostate cancer and high-grade prostate cancer. 
Feature 
PCa HGPCa 
OR (95% CI) p Value OR (95% CI) p Value 
Age, years 1.068 (1.050–1.087) 0.001 1.128 (1.091–1.167) 0.001 
Serum PSA, ng/mL 1.021 (1.005–1.038) 0.011 1.190 (1.142–1.240) 0.001 
Body mass index, kg/m2 1.004 (0.974–1.036) 0.785 0.983 (0.938–1.030 0.475 
Serum cholesterol,  
(<200 vs. >200 mg/dL) 
1.870 (1.557–2.245) 0.001 0.314 (0.226–0.436) 0.002 
Statins use (no vs. yes) 0.876 (0.725–1.059) 0.172 1.152 (0.816–1.626) 0.421 
The incidence of PCa and HGPCa is presented along with the flow rate of men, according to SC 
levels (first step) and then according to statins use (second step) (Figure 1). PCa was diagnosed in  
240 of the 912 men with NSC (26.3%), while it was diagnosed in 608 of the 1496 men with HSC 
(40.6%), OR 1.917 (95% CI 1.601–2.295), p < 0.001. HGPCa was detected in 129 of the men with 
NSC (53.8%) and in 168 of the men with HSC (27.6%), OR 0.329 (95% CI 0.241–0.448), p < 0.001. 
In the subset of men with NSC, 392 (43.0%) were statin users and 520 (57.0%) were non-statin users. 
PCa was detected in 104 (26.5%) men and 136 (26.2%) men, respectively, OR 1.020 (95% CI  
0.757–1.373), p = 0.939. HGPCa was detected in 73 (70.2%) men and 56 (41.2%) men, respectively, 
OR: 3.364, (95% CI 1.958–5.781), p < 0.001. In the subset of men with HSC, 352 (23.5%) were statin 
users and 1144 (76.5%) were non-statin users. PCa was detected in 128 (36.4%) men and 480 (42.0%) 
men, respectively, OR 0.790 (95% CI 0.618–1.012), p = 0.063. HGPCa was detected in 24 (18.8%) 
men and 144 (30.0%) men, respectively, OR 0.538 (95% CI 0.232–0.874), p = 0.011. 
2.2. Discussion 
There is already a strong foundation of basic scientific research that demonstrates how statins 
inhibit many pathways of cancer formation and progression through cholesterol and non-cholesterol 
mediated mechanisms [26]. However, those specific cholesterol-mediated mechanisms have presented 
a challenge in prostate cancer, especially after a study conducted on the placebo arm of the prostate 
cancer prevention trial. That particular study suggested that men with low cholesterol levels present  
a reduced risk for high-grade tumors, but not for the overall risk of prostate cancer. Nevertheless,  
the results in that study were not adjusted to reflect the use of cholesterol-lowering drugs [13].  
A recent, nested case-control study investigating low-circulating cholesterol as a possible mechanism 
underlying the statins findings reported that men with low plasma cholesterol also had a lower risk for 
high-grade tumors, though not for an overall risk of prostate cancer. In that study, the inverse 
association with high-risk tumors persisted after excluding users of cholesterol-lowering drugs, 
suggesting that cholesterol itself may play a role. 
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Figure 1. Risk of prostate cancer (PCa) detection and high-grade PCa detection according 
to the quality of serum cholesterol level and chronic statin use. PB, prostatic biopsy;  
*, p < 0.0001, OR: 1.917 (95% Cl 1.601–2.295); **, p < 0.001, OR: 0.329 (95% Cl  
0.241–0.448); †, p = 0.939, OR: 1.020 (95% Cl 0.757–1.373); ††, p < 0.001, OR: 3.263 
(95% Cl 1.975–5.781); ∫, p = 0.063, OR: 0.790 (95% Cl 0.618–1.012); ∫∫, p < 0.011,  
OR: 0.538 (95% Cl 0.332–0.874). 
 
Our study suggests the truth of the hypothesis that links the effect of statins used to reduce serum 
cholesterol levels to prostate carcinogenesis. For our research, we selected a population at high risk for 
prostate cancer detection. We mainly observed a significant association between serum cholesterol 
levels and the risk of prostate cancer detection. This association was observed independently of 
chronic statins use. This cohort had a 35% rate of prostate cancer detection, which decreased to 26%  
in men with low serum cholesterol levels and increased to 40% in men with high serum cholesterol 
levels. Moreover, the decrease in the prostate cancer detection rate was similar in men with low 
cholesterol levels independent of chronic statins use. These findings concur with a recent study by 
Murtola, et al., which analyzed the influence of statins use in a Finnish cohort of 23,320 men subjected 
to systematic prostate cancer screening [27]. They observed a low overall prostate cancer incidence 
among statin users when the bias between users and non-users, due to differential PSA testing,  
was eliminated. In our study, we observed a 36% rate of prostate cancer detection in statin non-users 
with high serum cholesterol, while the rate for those men with high serum cholesterol who used statins 
was 42%. These results suggest that the role of statins in prostate cancer prevention could be restricted 
to those men, whose serum cholesterol levels were normalized after statins use. It was interesting  
to observe that our logistic regression analysis confirmed that serum cholesterol levels were an independent 
predictor of prostate cancer detection, though in the case of chronic statin use, they were not. 
As we have observed, some epidemiological studies have found an inverse association between 
serum cholesterol levels and prostate cancer incidence [7,8,27]. A recent study, conducted on a cohort 
of 12,996 men with a follow-up of 37 years, suggested that men with high serum cholesterol are at 
greater risk of being diagnosed with high-grade prostate cancer tumors, though not at a greater overall risk 
of prostate cancer detection [15]. For this reason, we believe that a well-designed prospective study should 
be conducted to elucidate the exact role of statins use in prostate cancer chemoprevention. 
2408 men subjected to PB 
Serum cholesterol < 200  md/dL 
 
Men:  912 (37.9%) 
PC: 240 (26.3%)* 
HGPC: 129 (53.8%)**  
Serum cholesterol > 200  md/dL 
 
Men: 1496 (62.1%) 
PC: 608 (40.6%)* 
HGPC: 168 (27.6%)**  
With statins 
 
Men: 392 (43.0%) 
PC: 104 (26.5%)† 
HGPC: 73 (70.2%)†† 
Without  statins 
 
Men: 520 (57.0%) 
PC: 136 (26.2%)† 
HGPC: 56 (41.2%) †† 
With statins 
 
Men: 352 (23.5%) 
PC: 128 (36.4%)∫  
HGPC: 24 (18.8%)∫∫  
Without  statins 
 
Men: 1144 (76.5%) 
PC: 480 (42.0%)∫  
HGPC: 144 (30.0%)∫∫  
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Several mechanisms, by which cholesterol and prostate carcinogenesis may be linked, have been 
proposed. Prostate cancer cells tend to over-accumulate cholesterol in their cell membranes forming 
large lipid rafts, which may facilitate pro-carcinogenic cell signaling in the cancer cells. Moreover, 
several other pathways considered to be vital in carcinogenesis, such as sonic hedgehog and Akt 
pathways, are also cholesterol sensitive. Thus, having lower cholesterol levels may inhibit these  
pro-carcinogenic activities in prostate cells [28]. Our study suggests the hypothesis that statins can 
prevent prostate cancer development through a cholesterol-mediated mechanism. 
A critical point of our study was to determine the aggressiveness of detected tumors with relation to 
the use of statins and the induced changes in serum cholesterol levels. We founded a disturbingly 
increased rate of high-grade tumors in statin users with normalized serum cholesterol, while the rate 
was very low in those men with high serum cholesterol who did not use statins. The interpretation of 
these results presents a challenge, since most of the recent reports have suggested an association 
between low cholesterol levels and a lesser probability of high-grade tumors [11–13]. However, none 
of those studies related this fact to statin consumption. Again, it is interesting to examine the Finnish 
group’s study on statins use in their prostate cancer screening trial [26]. In that study, statin users had  
a significantly decreased risk of being diagnosed with tumors having a Gleason score of 2 to 6 with 
respect to non-users. However, this significant decrease was not seen in tumors with Gleason scores of 
7 to 10 or advanced tumors. The Finnish group’s and our results conflict with the widely held view  
that statins prevent aggressive tumors. We would like to emphasize, once again, that a well-designed 
prospective study is needed to determine whether statins are able to prevent aggressive tumors. 
Admittedly, our study suffers from the many weaknesses encountered in most case and control 
studies. It is not a prospective cohort and controlled study. We selected a population with a high risk 
for prostate cancer detection; however, due to the influence of statins in the serum PSA, a selection 
bias for prostate biopsy could have modified the results. The influence of some lifestyle habits, 
comorbidities, and other concomitant treatments in prostatic carcinogenesis can also act as confounders. 
The criteria for defining chronic treatment, three years, may also have introduced a bias, as well as the 
specific statins used and their dosage. 
3. Patients and Methods 
Patients: Between January 2006 and December 2011 we conducted a prospective study on lifestyle 
habits, metabolic and cardiovascular comorbidities, and concomitant treatments in 3281 Mediterranean 
men scheduled for prostatic biopsy (PB), due to PSA levels above 4 ng/mL and/or an abnormal digital 
rectal examination. All participants received detailed information about the study procedure and 
provided written informed consent for PB and participation in the study. All procedures were in 
accordance with the ethical standards established in our country. Internal review board approval was 
not required for such a non-experimental study. All patients were given a questionnaire and underwent 
physical examination (size, weight, abdominal waist measurement and blood pressure assessment) and 
laboratory profile screening. Patients were asked about the use and duration of statins treatment and their 
serum cholesterol levels (SC) were determined. 
To carry out this analysis, 2408 men were selected, after excluding those men who were undergoing 
5-α-reductase inhibitors treatment and those men who had been using statins for less than three years. 
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SC was classified as normal (NSC) at <200 mg/dL and high (HSC) at >200 mg/dL [11]. PCa was 
detected in 848 men (35.2%), and 240 (28.3%) were HGPCa (Gleason score > 7). The overall 
demographics and clinical characteristics of the men enrolled are summarized in Table 4. 
Table 4. Overall demographics and clinical characteristics of enrolled men. 
Clinical Feature Measurement 
Men, no (%) 2408 (100) 
Age, years * 68 (46–86) 
Body mass index * 27.6 (18.4–46.0) 
Serum PSA *, ng/mL 6.9 (0.7–1280) 
Serum cholesterol *, mg/dL 212 (101–309) 
Statins treatment (%) 744 (30.9) 
Prostate cancer detection 848 (35.2) 
Gleason score 8–10 (%) 240 (28.3%) 
*, values expressed in median (range). 
Prostate biopsy technique: Transrectal ultrasound guided PB was performed as an outpatient 
procedure under local anesthesia. An end-fire ultrasound transducer (Falcon 2101, B-K Medical, Inc., 
Peabody, MA, USA) and a 16-gauge automated biopsy needle (Bard, Inc., Covington, GA, USA) were 
used. A minimum of 10 cores were obtained, and from 2 to 8 additional ones were taken based on age 
and prostate volume, according to a modified Vienna nomogram [29]. 
Statistical analysis: Quantitative variables were expressed as medians + semi-interquartile range 
(range). Qualitative variables were expressed as rates. Univariate analysis included the Chi-square test 
to analyze the association between qualitative variables and the Cochran test to evaluate their strength. 
The Mann–Whitney U test was performed to compare quantitative variables. Multivariate analysis 
using the binary logistic regression was carried out to examine the independent predictors of PCa risk 
and tumor aggressiveness. Odds ratios (OR) and 95% CI were calculated. The SPSS program V.20 
(IBM, Chicago, IL, USA) was used to perform this statistical analysis. 
4. Conclusions 
We would like to conclude with the following hypothesis: Statins may prevent prostate cancer 
development by lowering cholesterol levels. Tumor aggressiveness may be related to the effectiveness 
of statins in normalizing cholesterol levels. In conjunction with our hypothesis, we would like to 
include this stipulation: In the future, a prospective and well-designed study considering statins 
consumption, as well as cholesterol levels, is required in order to clarify the specific role of statins in 
the chemoprevention of prostate cancer. 
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